Price Don’t Lie: Insys Therapeutics Inc Can’t Be More Risky. Just Reaches 1 Year Low

Price Don't Lie: Insys Therapeutics Inc Can't Be More Risky. Just Reaches 1 Year Low

The stock of Insys Therapeutics Inc (NASDAQ:INSY) hit a new 52-week low and has $10.25 target or 7.00% below today’s $11.02 share price. The 5 months bearish chart indicates high risk for the $738.50M company. The 1-year low was reported on Oct, 17 by If the $10.25 price target is reached, the company will be worth $51.70 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 277,878 shares traded hands. Insys Therapeutics Inc (NASDAQ:INSY) has declined 41.50% since March 14, 2016 and is downtrending. It has underperformed by 47.12% the S&P500.

Analysts await Insys Therapeutics Inc (NASDAQ:INSY) to report earnings on November, 3. INSY’s profit will be $4.02 million for 45.92 P/E if the $0.06 EPS becomes a reality. After $0.06 actual earnings per share reported by Insys Therapeutics Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Insys Therapeutics Inc (NASDAQ:INSY) Ratings Coverage

Out of 4 analysts covering Insys Therapeutics (NASDAQ:INSY), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Insys Therapeutics has been the topic of 9 analyst reports since August 4, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Tuesday, April 12 by Jefferies. RBC Capital Markets maintained Insys Therapeutics Inc (NASDAQ:INSY) on Thursday, September 22 with “Outperform” rating. Jefferies maintained the shares of INSY in a report on Thursday, August 4 with “Buy” rating. The stock has “Hold” rating given by Oppenheimer on Tuesday, August 4. JMP Securities maintained the stock with “Market Outperform” rating in Wednesday, March 9 report. Zacks downgraded the shares of INSY in a report on Friday, August 14 to “Buy” rating. The firm has “Buy” rating by Jefferies given on Wednesday, February 24. The rating was maintained by Jefferies with “Buy” on Monday, October 10. Janney Capital initiated Insys Therapeutics Inc (NASDAQ:INSY) rating on Thursday, April 14. Janney Capital has “Buy” rating and $22 price target.

According to Zacks Investment Research, “Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company’s cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray and Dronabinol SG capsule. Insys Therapeutics, Inc. is based in Phoenix, Arizona.”

Insitutional Activity: The institutional sentiment decreased to 0.7 in Q2 2016. Its down 0.36, from 1.06 in 2016Q1. The ratio turned negative, as 22 funds sold all Insys Therapeutics Inc shares owned while 42 reduced positions. 13 funds bought stakes while 32 increased positions. They now own 31.30 million shares or 9.76% less from 34.69 million shares in 2016Q1.
Citigroup Inc owns 18,511 shares or 0% of their US portfolio. Wellington Mgmt Llp accumulated 125,405 shares or 0% of the stock. Rock Springs Capital Mngmt Limited Partnership has 0.35% invested in the company for 365,500 shares. Fin Architects last reported 6 shares in the company. Dimensional Fund Advsrs L P owns 581,756 shares or 0% of their US portfolio. Price T Rowe Associate Md holds 0% or 114,660 shares in its portfolio. Tiaa Cref Invest Limited Co accumulated 0% or 71,454 shares. Victory Capital Management Incorporated holds 0% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY) for 3,313 shares. 12 West Cap L P, a New York-based fund reported 623,791 shares. Antipodean Advsr Limited Liability Co reported 305,294 shares or 2.39% of all its holdings. Fmr Limited Company holds 0% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY) for 794,645 shares. Strs Ohio holds 125,000 shares or 0.01% of its portfolio. Pictet Asset Mgmt Limited has 0.01% invested in the company for 87,426 shares. Parametric Portfolio Assocs Llc accumulated 15,197 shares or 0% of the stock. New York State Common Retirement Fund holds 22,700 shares or 0% of its portfolio.

Insider Transactions: Since May 11, 2016, the stock had 2 insider buys, and 4 selling transactions for $170,592 net activity. Another trade for 16,000 shares valued at $260,320 was sold by STANLEY THEODORE H. Shares for $110,752 were sold by BRENNAN DANIEL on Tuesday, August 9. $276,900 worth of Insys Therapeutics Inc (NASDAQ:INSY) was sold by FOURTEAU PATRICK. Shares for $641,827 were bought by JOHN N KAPOOR TRUST DATED SEPTEMBER 20 1989 on Wednesday, May 11.

More news for Insys Therapeutics Inc (NASDAQ:INSY) were recently published by:, which released: “Research Reports Coverage on Biotech Stocks — Immunomedics, ImmunoGen, INSYS …” on October 17, 2016.‘s article titled: “Insys Therapeutics Announces CEO Succession Plan” and published on September 21, 2016 is yet another important article.

INSY Company Profile

Insys Therapeutics, Inc., incorporated on June 15, 1990, is a commercial-stage specialty pharmaceutical company. The Firm develops and commercializes supportive care products. Subsys is the Company’s marketed product. Subsys is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and is a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Firm markets Subsys through its field sales force focused on supportive care physicians in the United States.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment